Household & Personal Products · Founded 1964 · www.in.pg.com · BSE 500459 · NSE PROCTER &GAM · ISIN INE179A01014
No Notes Added Yet
1. Business Overview
Procter & Gamble Hygiene and Health Care Ltd. (PGHH) is an Indian subsidiary of the global consumer goods giant Procter & Gamble. The company is primarily engaged in the manufacturing, marketing, and sale of a range of hygiene and healthcare products in India. Its core business model revolves around developing strong brands, leveraging extensive distribution networks, and consistent marketing to reach consumers. PGHH generates revenue by selling products such as Vicks (cold and cough remedies), Whisper (feminine hygiene products), and Old Spice (men's grooming products) through various retail channels across urban and rural India.
2. Key Segments / Revenue Mix
PGHH's revenue is primarily derived from two main product categories:
Healthcare: This segment includes products like Vicks VapoRub, Vicks Cough Drops, and Vicks Inhaler, targeting cold, cough, and flu relief.
Feminine Care: This segment is dominated by the Whisper brand, offering a range of sanitary pads and related feminine hygiene products.
Grooming: This segment includes Old Spice, primarily men's deodorants and body sprays.
While specific revenue percentages fluctuate, Healthcare and Feminine Care generally represent the dominant portions of the company's sales.
3. Industry & Positioning
PGHH operates within the highly competitive Indian Household & Personal Products industry, which is part of the larger Fast-Moving Consumer Goods (FMCG) sector. The industry is characterized by the presence of both large multinational corporations (MNCs) and strong domestic players. PGHH holds a leading position in its specific product categories; for example, Vicks is a strong player in the over-the-counter cold and cough market, and Whisper holds a significant market share in the feminine hygiene segment. The company leverages its global parent's expertise and brand strength to maintain its competitive standing.
4. Competitive Advantage (Moat)
PGHH possesses several durable competitive advantages:
Strong Brand Equity: Brands like Vicks and Whisper are household names in India, enjoying high consumer recall, trust, and loyalty built over decades.
Extensive Distribution Network: The company benefits from P&G's robust and deep distribution reach across urban and rural India, ensuring product availability.
R&D and Innovation: Backed by P&G's global R&D capabilities, PGHH can introduce innovative products and improve existing ones, adapting to local consumer needs.
Scale and Marketing Prowess: As part of a global giant, PGHH benefits from economies of scale in sourcing and manufacturing, and possesses significant marketing and advertising budgets to sustain brand visibility.
5. Growth Drivers
Key factors that can drive PGHH's growth over the next 3-5 years include:
Increasing Health & Hygiene Awareness: Growing awareness, particularly post-pandemic, for hygiene and health products can drive demand for Vicks and Whisper.
Rising Disposable Incomes & Premiumization: Growth in middle-class disposable incomes in India can lead to higher adoption rates and demand for premium product offerings.
Untapped Rural Markets: Expansion into Tier 2, Tier 3 cities, and deeper rural penetration for categories like feminine hygiene presents significant growth potential.
Category Expansion & Innovation: Introducing new product variants, sizes, and potentially expanding into adjacent categories under existing strong brands.
Digital Adoption: Increasing e-commerce penetration and digital marketing efforts can enhance reach and sales efficiency.
6. Risks
Intense Competition: The Indian FMCG market is highly competitive, with strong players like Hindustan Unilever, ITC, and numerous regional brands, leading to pricing pressures and market share battles.
Raw Material Price Volatility: Fluctuations in global commodity prices for raw materials can impact manufacturing costs and gross margins.
Regulatory Changes: Changes in health product regulations, advertising standards, or taxation policies (e.g., GST) can affect business operations and profitability.
Consumer Preference Shifts: Rapid changes in consumer preferences, new entrants, or lack of timely innovation can erode brand loyalty and market share.
Supply Chain Disruptions: Geopolitical events, natural disasters, or infrastructure issues can disrupt the supply chain, impacting production and distribution.
7. Management & Ownership
PGHH is promoted by Procter & Gamble, a global leader in consumer goods. The company operates with a professional management team, adhering to the high standards and strategic direction set by its parent company. The ownership structure typically involves Procter & Gamble holding a significant majority stake, with the remaining shares being publicly traded on Indian stock exchanges. This structure provides PGHH access to global resources, expertise, and best practices, while also having an independent board and management to oversee its Indian operations.
8. Outlook
PGHH benefits from a strong portfolio of established brands (Vicks, Whisper) that enjoy high consumer trust and extensive distribution in India. The underlying growth drivers of increasing health awareness, rising disposable incomes, and untapped market potential, particularly in feminine hygiene, provide a favorable backdrop for sustained growth. However, the company operates in a fiercely competitive market, necessitating continuous innovation, aggressive marketing, and efficient cost management to maintain its market leadership. Risks such as raw material inflation, shifts in consumer preferences, and intense competition will require vigilant strategic execution to navigate successfully. The strong backing of its global parent company provides a significant advantage in terms of R&D, brand building, and operational expertise.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1138 | 1133 | 1002 | 932 | 1135 | 1248 | 992 | 937 | 1150 | 1262 |
| Other Income | 16 | 16 | 14 | 7 | 9 | 10 | 19 | 8 | 10 | 12 |
| Total Income | 1154 | 1149 | 1016 | 939 | 1144 | 1257 | 1011 | 945 | 1160 | 1274 |
| Total Expenditure | 853 | 824 | 745 | 813 | 845 | 877 | 782 | 671 | 865 | 860 |
| Operating Profit | 301 | 325 | 271 | 126 | 299 | 381 | 229 | 274 | 295 | 414 |
| Interest | 2 | 3 | 22 | -0 | 2 | 7 | 6 | 0 | 4 | 3 |
| Depreciation | 14 | 14 | 15 | 13 | 12 | 10 | 10 | 9 | 9 | 10 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 284 | 309 | 234 | 112 | 285 | 364 | 213 | 265 | 282 | 402 |
| Provision for Tax | 74 | 80 | 80 | 31 | 73 | 96 | 57 | 73 | 72 | 101 |
| Profit After Tax | 211 | 229 | 154 | 81 | 212 | 269 | 156 | 192 | 210 | 301 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 211 | 229 | 154 | 81 | 212 | 269 | 156 | 192 | 210 | 301 |
| Adjusted Earnings Per Share | 64.9 | 70.5 | 47.6 | 25 | 65.3 | 82.7 | 48.1 | 59.2 | 64.7 | 92.9 |
| #(Fig in Cr.) | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 2334 | 2275 | 2320 | 2455 | 2947 | 3002 | 3574 | 3901 | 3918 | 4206 | 3374 | 4341 |
| Other Income | 76 | 88 | 79 | 24 | 55 | 44 | 56 | 30 | 45 | 68 | 38 | 49 |
| Total Income | 2409 | 2363 | 2399 | 2479 | 3002 | 3046 | 3630 | 3931 | 3963 | 4273 | 3413 | 4390 |
| Total Expenditure | 1850 | 1670 | 1658 | 1840 | 2339 | 2398 | 2706 | 3077 | 3054 | 3251 | 2504 | 3178 |
| Operating Profit | 559 | 693 | 742 | 639 | 663 | 648 | 924 | 854 | 909 | 1023 | 908 | 1212 |
| Interest | 6 | 6 | 10 | 5 | 5 | 6 | 6 | 11 | 11 | 27 | 14 | 13 |
| Depreciation | 53 | 52 | 60 | 52 | 50 | 48 | 48 | 53 | 58 | 57 | 32 | 38 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 501 | 636 | 672 | 582 | 607 | 594 | 870 | 790 | 839 | 939 | 862 | 1162 |
| Provision for Tax | 155 | 213 | 239 | 207 | 188 | 161 | 218 | 214 | 161 | 264 | 226 | 303 |
| Profit After Tax | 346 | 423 | 433 | 375 | 419 | 433 | 652 | 576 | 678 | 675 | 637 | 859 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 346 | 423 | 433 | 375 | 419 | 433 | 652 | 576 | 678 | 675 | 637 | 859 |
| Adjusted Earnings Per Share | 106.6 | 130.2 | 133.3 | 115.4 | 129.1 | 133.4 | 200.8 | 177.4 | 208.9 | 208 | 196.1 | 264.9 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -20% | -5% | 2% | 4% |
| Operating Profit CAGR | -11% | 2% | 7% | 5% |
| PAT CAGR | -6% | 3% | 8% | 6% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -32% | -11% | -6% | 4% |
| ROE Average | 91% | 86% | 83% | 60% |
| ROCE Average | 116% | 110% | 107% | 82% |
| #(Fig in Cr.) | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 1229 | 1652 | 526 | 806 | 909 | 1158 | 714 | 738 | 946 | 775 | 737 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | -1 | -5 | 25 | 26 | 29 | 46 | 45 | 33 | 41 | 28 | 34 |
| Total Current Liabilities | 716 | 511 | 582 | 571 | 642 | 595 | 835 | 860 | 1085 | 981 | 901 |
| Total Liabilities | 1944 | 2157 | 1134 | 1402 | 1580 | 1799 | 1595 | 1631 | 2072 | 1784 | 1672 |
| Fixed Assets | 309 | 317 | 286 | 250 | 234 | 207 | 184 | 164 | 170 | 139 | 131 |
| Other Non-Current Assets | 278 | 208 | 245 | 316 | 256 | 264 | 294 | 332 | 406 | 445 | 434 |
| Total Current Assets | 1357 | 1632 | 603 | 815 | 1069 | 1321 | 1117 | 1135 | 1496 | 1200 | 1091 |
| Total Assets | 1944 | 2157 | 1134 | 1402 | 1580 | 1799 | 1595 | 1631 | 2072 | 1784 | 1672 |
| #(Fig in Cr.) | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 266 | 615 | 1067 | 102 | 392 | 526 | 884 | 648 | 625 | 964 | 574 |
| Cash Flow from Operating Activities | 426 | 352 | 445 | 415 | 413 | 474 | 863 | 573 | 826 | 470 | 593 |
| Cash Flow from Investing Activities | 28 | 221 | 149 | -19 | 34 | 75 | 7 | -27 | -10 | 1 | -34 |
| Cash Flow from Financing Activities | -105 | -122 | -1559 | -106 | -314 | -190 | -1106 | -569 | -477 | -861 | -666 |
| Net Cash Inflow / Outflow | 349 | 452 | -964 | 290 | 134 | 358 | -236 | -23 | 339 | -390 | -107 |
| Closing Cash & Cash Equivalent | 615 | 1067 | 102 | 392 | 526 | 884 | 648 | 625 | 964 | 574 | 466 |
| # | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 106.64 | 130.16 | 133.31 | 115.4 | 129.12 | 133.42 | 200.8 | 177.37 | 208.92 | 207.95 | 196.12 |
| CEPS(Rs) | 122.82 | 146.08 | 151.72 | 131.53 | 144.46 | 148.17 | 215.48 | 193.66 | 226.89 | 225.36 | 205.96 |
| DPS(Rs) | 30.25 | 36 | 389 | 40 | 88 | 105 | 315 | 160 | 185 | 255 | 175 |
| Book NAV/Share(Rs) | 378.52 | 507.78 | 159.65 | 244.05 | 274.67 | 349.7 | 210.9 | 214.95 | 276.56 | 221.21 | 212.1 |
| Core EBITDA Margin(%) | 20.49 | 25.79 | 27.4 | 25.06 | 20.61 | 20.11 | 24.28 | 17.73 | 18.5 | 18.91 | 20.75 |
| EBIT Margin(%) | 21.46 | 27.32 | 28.2 | 23.91 | 20.8 | 19.98 | 24.51 | 17.24 | 18.22 | 19.14 | 20.9 |
| Pre Tax Margin(%) | 21.22 | 27.05 | 27.77 | 23.69 | 20.61 | 19.78 | 24.34 | 17 | 17.97 | 18.6 | 20.56 |
| PAT Margin (%) | 14.67 | 17.99 | 17.89 | 15.26 | 14.22 | 14.43 | 18.24 | 12.39 | 14.52 | 13.37 | 15.18 |
| Cash Profit Margin (%) | 16.89 | 20.18 | 20.36 | 17.39 | 15.91 | 16.02 | 19.57 | 13.52 | 15.77 | 14.49 | 15.94 |
| ROA(%) | 20.1 | 20.6 | 26.3 | 29.54 | 28.1 | 25.63 | 38.41 | 35.7 | 36.63 | 35.02 | 36.84 |
| ROE(%) | 31.02 | 29.37 | 39.95 | 57.17 | 49.79 | 42.74 | 71.64 | 83.3 | 85.01 | 83.56 | 90.52 |
| ROCE(%) | 45.4 | 44.56 | 62.65 | 88.18 | 71.48 | 58.05 | 93.58 | 110.39 | 101.08 | 112.29 | 115.95 |
| Receivable days | 15.47 | 20.48 | 21.31 | 20.91 | 20.43 | 21.14 | 15.76 | 13.13 | 15.95 | 16.52 | 23.72 |
| Inventory Days | 18.37 | 19.15 | 23 | 22.37 | 20.25 | 24.83 | 23.2 | 18.97 | 17.73 | 16.1 | 19.45 |
| Payable days | 119.33 | 143.65 | 137.09 | 148.01 | 140.88 | 178.06 | 202.36 | 179.52 | 192.14 | 206.08 | 241.53 |
| PER(x) | 63.52 | 48.24 | 60.36 | 85.8 | 82.91 | 76.11 | 66.38 | 75.57 | 68.47 | 79.92 | 69.36 |
| Price/Book(x) | 17.89 | 12.37 | 50.4 | 40.57 | 38.98 | 29.04 | 63.2 | 62.36 | 51.72 | 75.14 | 64.14 |
| Dividend Yield(%) | 0.45 | 0.57 | 4.83 | 0.4 | 0.82 | 1.03 | 2.36 | 1.19 | 1.29 | 1.53 | 1.29 |
| EV/Net Sales(x) | 9.16 | 8.49 | 11.21 | 12.93 | 11.61 | 10.68 | 11.92 | 10.99 | 11.6 | 12.69 | 12.94 |
| EV/Core EBITDA(x) | 38.22 | 27.84 | 35.05 | 49.64 | 51.63 | 49.49 | 46.13 | 50.19 | 49.99 | 52.18 | 48.08 |
| Net Sales Growth(%) | 13.79 | -2.5 | 1.98 | 5.81 | 20.02 | 1.87 | 19.06 | 9.14 | 0.44 | 7.35 | -19.77 |
| EBIT Growth(%) | 8.77 | 26.7 | 6.3 | -13.94 | 4.38 | -2.1 | 46.01 | -8.52 | 6.18 | 13.56 | -9.29 |
| PAT Growth(%) | 14.61 | 22.06 | 2.42 | -13.44 | 11.89 | 3.33 | 50.5 | -11.67 | 17.78 | -0.46 | -5.69 |
| EPS Growth(%) | 14.61 | 22.06 | 2.42 | -13.44 | 11.89 | 3.33 | 50.5 | -11.67 | 17.78 | -0.46 | -5.69 |
| Debt/Equity(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio(x) | 1.9 | 3.19 | 1.04 | 1.43 | 1.66 | 2.22 | 1.34 | 1.32 | 1.38 | 1.22 | 1.21 |
| Quick Ratio(x) | 1.73 | 2.94 | 0.73 | 1.21 | 1.35 | 1.87 | 1.04 | 1.05 | 1.18 | 0.99 | 0.96 |
| Interest Cover(x) | 88.55 | 102.36 | 65.47 | 110.36 | 111.83 | 98.84 | 143.37 | 71.61 | 74.77 | 35.79 | 61.29 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 70.64 | 70.64 | 70.64 | 70.64 | 70.64 | 70.64 | 70.64 | 70.64 | 70.64 | 70.64 |
| FII | 1.48 | 1.57 | 1.56 | 1.48 | 1.43 | 1.33 | 1.38 | 1.11 | 1.07 | 0.97 |
| DII | 15.29 | 15.11 | 15.16 | 15.28 | 15.37 | 15.51 | 15.49 | 16.05 | 16.04 | 15.97 |
| Public | 12.59 | 12.68 | 12.65 | 12.6 | 12.56 | 12.52 | 12.48 | 12.19 | 12.26 | 12.43 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 2.29 | 2.29 | 2.29 | 2.29 | 2.29 | 2.29 | 2.29 | 2.29 | 2.29 | 2.29 |
| FII | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 |
| DII | 0.5 | 0.49 | 0.49 | 0.5 | 0.5 | 0.5 | 0.5 | 0.52 | 0.52 | 0.52 |
| Public | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.4 | 0.4 | 0.4 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 70.64 | 70.64 | 70.64 | 70.64 | 70.64 | 70.64 | 70.64 | 70.64 | 70.64 | 70.64 |
| FII | 1.48 | 1.57 | 1.56 | 1.48 | 1.43 | 1.33 | 1.38 | 1.11 | 1.07 | 0.97 |
| DII | 15.29 | 15.11 | 15.16 | 15.28 | 15.37 | 15.51 | 15.49 | 16.05 | 16.04 | 15.97 |
| Public | 29.36 | 29.36 | 29.36 | 29.36 | 29.36 | 29.36 | 29.36 | 29.36 | 29.36 | 29.36 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 2.29 | 2.29 | 2.29 | 2.29 | 2.29 | 2.29 | 2.29 | 2.29 | 2.29 | 2.29 |
| FII | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 |
| DII | 0.5 | 0.49 | 0.49 | 0.5 | 0.5 | 0.5 | 0.5 | 0.52 | 0.52 | 0.52 |
| Public | 0.95 | 0.95 | 0.95 | 0.95 | 0.95 | 0.95 | 0.95 | 0.95 | 0.95 | 0.95 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -20% | -5% | +2% | +4% |
| Operating Profit CAGR | -11% | +2% | +7% | +5% |
| PAT CAGR | -6% | +3% | +8% | +6% |
| Share Price CAGR | -32% | -11% | -6% | +4% |
| ROE Average | +91% | +86% | +83% | +60% |
| ROCE Average | +116% | +110% | +107% | +82% |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.